Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Novartis
Merck
Teva
Federal Trade Commission
McKinsey
Moodys
Citi
Baxter
US Department of Justice
Argus Health

Generated: August 22, 2017

DrugPatentWatch Database Preview

ADDYI Drug Profile

« Back to Dashboard

Which patents cover Addyi, and what generic Addyi alternatives are available?

Addyi is a drug marketed by Sprout Pharms and is included in one NDA. There are four patents protecting this drug.

This drug has seventy-four patent family members in thirty-one countries.

The generic ingredient in ADDYI is flibanserin. One supplier is listed for this compound. Additional details are available on the flibanserin profile page.

Summary for Tradename: ADDYI

Patents:4
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list23
Clinical Trials: see list2
Patent Applications: see list222
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ADDYI at DailyMed

Pharmacology for Tradename: ADDYI

Mechanism of ActionP-Glycoprotein Inhibitors
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sprout Pharms
ADDYI
flibanserin
TABLET;ORAL022526-001Aug 18, 2015RXYesYes► Subscribe► SubscribeYY ► Subscribe
Sprout Pharms
ADDYI
flibanserin
TABLET;ORAL022526-001Aug 18, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Sprout Pharms
ADDYI
flibanserin
TABLET;ORAL022526-001Aug 18, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Sprout Pharms
ADDYI
flibanserin
TABLET;ORAL022526-001Aug 18, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Sprout Pharms
ADDYI
flibanserin
TABLET;ORAL022526-001Aug 18, 2015RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: ADDYI

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,183,410Stable polymorph of flibanserin► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ADDYI

Country Document Number Estimated Expiration
South Korea20040023704► Subscribe
Japan2004537597► Subscribe
Argentina077480► Subscribe
South Africa200309586► Subscribe
China1551879► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
Fuji
Covington
Julphar
Colorcon
Medtronic
Novartis
Moodys
Boehringer Ingelheim
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot